Table A, Selectivity profile of Cpd-1, Cpd-2, and Cpd-3 for critical oncology-related kinases.

Table B, Top 50 transcripts lacking exons through exon skipping in cells treated with Cpd-2 for 24 h. Table C, Top 50 transcripts with alternative donor/acceptor splice sites in cells treated with Cpd-2 for 24 h. Table D, Top 50 Gene Ontology results for genes lacking exons through exon skipping in cells treated with Cpd-2 for 24 h. The P-values were obtained by Fisher’s exact test for statistically significant differences. Table E, Top 50 transcripts, encoding proteins involved in cell growth and survival, lacking exons through exon skipping in cells treated with Cpd-2 for 24 h. Table F, List of primers, TaqMan MGB probes, and ASO sequences. Fig. A, Analysis of gene expression in cells treated with SRPK1 and SRPK2 siRNAs. MDA-MB-468 cells were transfected with SRPK1 siRNA, SRPK2 siRNA, or control Non-Silencing siRNA (NS). Cells were harvested after 24, 48, and 72 h of treatment. (A) The expression level of each gene was measured by quantitative RT-PCR. (B) The expression levels of S6K exons 6–7 (normal mRNA) and S6K exons 6–8 (aberrant splicing variant with skipped exon 7) were determined by quantitative RT-PCR. The data represent means ± SD from three independent analyses.
(DOC)